Bio News
U.S.-based Electra Therapeutics has applied to list on Nasdaq to raise funds for developing its immunology and oncology pipeline. Its lead candidate, isoflubat, is being evaluated in a global Phase 2/3 trial in patients with secondary hemophagocytic lymphohistiocytosis (sHLH). Electra Therapeutics also plans to use the proceeds from the offering to support the biologics license application for isoflubat and prepare for commercialization.
BIOBOOK TEAM
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
